Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have received an average recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $34.42.

A number of equities analysts recently weighed in on SNDX shares. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a report on Friday, January 19th. Scotiabank downgraded shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and lowered their target price for the stock from $36.00 to $23.00 in a report on Wednesday, January 31st. Finally, HC Wainwright restated a “buy” rating and set a $41.00 target price on shares of Syndax Pharmaceuticals in a report on Wednesday, March 27th.

Syndax Pharmaceuticals Stock Up 1.5 %

NASDAQ SNDX opened at $20.80 on Monday. Syndax Pharmaceuticals has a 12-month low of $11.22 and a 12-month high of $25.34. The company has a market capitalization of $1.77 billion, a PE ratio of -7.03 and a beta of 1.03. The firm’s 50 day moving average is $22.80 and its 200-day moving average is $19.37.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same quarter in the prior year, the business posted ($0.62) EPS. As a group, sell-side analysts expect that Syndax Pharmaceuticals will post -3.7 EPS for the current year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC increased its holdings in shares of Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after purchasing an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC bought a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at about $37,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals by 97.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock valued at $26,000 after acquiring an additional 880 shares during the period. Point72 Hong Kong Ltd bought a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at about $41,000. Finally, Quadrant Capital Group LLC boosted its position in shares of Syndax Pharmaceuticals by 158.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after acquiring an additional 1,496 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).